Maxygen, Inc. has achieved a $5 million preclinical milestone in its alliance with Roche to co-develop next-generation factor VIIa therapeutics. Maxygen achieved the milestone for development of a manufacturing process for its factor VIIa product candidates. In December 2005, Maxygen and Roche established an agreement to co-develop and commercialize next-generation factor VIIa products for multiple indications of severe bleeding, including trauma and intracerebral hemorrhage (ICH). Roche an...